Clinical Validation of ColonAiQ (a Blood-based Assay Targeting ctDNA Methylation) for Colorectal Cancer Detection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1965 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-31

Study Completion Date

2024-01-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The DNA methylation targets in preoperative plasma samples of the subjects will be detected by the multi-gene methylation test (ColonAiQ), and the test accuracy will be evaluated by compared with the clinical diagnosis evidence.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Prospective Cohort Study on Colorectal Cancer Screening in Community Population

NCT05485077

Colorectal Cancer

RECRUITING

An Exploratory Study on Gene Methylation Detection of Colorectal Cancer

NCT07033156

CRC (Colorectal Cancer) Adenoma Colon

RECRUITING

A Stool DNA Test for Detection of Advanced Colorectal Neoplasia in Asymptomatic Chinese Community Population

NCT04786704

Colorectal Cancer Colorectal Neoplasm Advanced Adenoma +2 more

COMPLETED

Early Screening of Colorectal Cancer Based on Plasma Multi-omics Combining With Artificial Intelligence

NCT05587452

Colorectal Adenoma Colorectal Cancer

UNKNOWN

Multiple Screening Methods for the Detection of Chinese Colorectal Advanced Adenomatous Polyps and Cancer

NCT03411707

Colorectal Cancer Colorectal Adenomatous Polyp

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The accuracy of ColonAiQ test in clinical testing will be evaluated in the multicenter, prospective study. Patients with colorectal cancer, intestinal polyps, adenomas and other non-neoplastic diseases of the digestive system, and patients with non-colorectal cancer such as gastric cancer, esophageal cancer, breast cancer and lung cancer will be enrolled. In this study, all cfDNA will be tested by fluorescence quantitative PCR, and some samples will be tested by NGS to verify the effectiveness of ColonAiQ test. Clinical diagnosis reports and methylation test results will be blinded to the lab tester and clinician respectively.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Colorectal cancer group

Patients who are 18 years of age and older and diagnosed with colorectal cancer.

ColonAiQ test and Colonoscopy

Intervention Type DIAGNOSTIC_TEST

Diagnostic Test

Control group

Patients with other non-neoplastic diseases of the digestive system, and patients with non-colorectal cancer such as gastric cancer, esophageal cancer, breast cancer and lung cancer, etc. as well as Individuals without any diseases checked by colonoscopy.

ColonAiQ test and Colonoscopy

Intervention Type DIAGNOSTIC_TEST

Diagnostic Test

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ColonAiQ test and Colonoscopy

Diagnostic Test

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥18 years old, gender is not limited;
2. meet one of the following conditions: 1) Suspected colorectal cancer (CRC); 2) Diagnosed with CRC according to clinical diagnostic criteria; 3) Do not have CRC and have interfering diseases:

1. Confirmed non-CRC digestive tract cases: colorectal polyps, adenomas, and other benign diseases of the digestive system;
2. Confirmed cases of other cancers other than CRC: gastric, esophageal, breast, and lung cancer;
3. diseases where the same gene methylation may be present (non-rheumatoid arthritis, etc.);
3. The subject or his/her guardian is able to understand the purpose of the study, demonstrate sufficient adherence to the study protocol, and sign the informed consent.

Exclusion Criteria

1. People who cannot tolerate relevant tests for clinical diagnosis;
2. Pregnant women;
3. Patients who have previously received colorectal cancer surgery, tumor drug therapy, neoadjuvant therapy, or radiotherapy;
4. Other conditions deemed unsuitable for inclusion by the investigator.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes